Epilepsy (generalised seizures).

BMJ clinical evidence Pub Date : 2015-04-17

J Helen Cross

{"title":"Epilepsy (generalised seizures).","authors":"J Helen Cross","doi":"","DOIUrl":null,"url":null,"abstract":"Introduction: About 3% of people will be diagnosed with epilepsy during their lifetime, but about 70% of people with epilepsy eventually go into remission.Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of additional treatments in people with drug-resistant epilepsy characterised by generalised seizures? We searched: Medline, Embase, The Cochrane Library, and other important databases up to April 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).Results: We found four studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.Conclusions: In this systematic review we present information relating to the effectiveness and safety on the addition of the following interventions: lacosamide, lamotrigine, levetiracetam, perampanel, and zonisamide versus the addition of placebo.","PeriodicalId":72432,"journal":{"name":"BMJ clinical evidence","volume":"2015 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400652/pdf/2015-1201.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ clinical evidence","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: About 3% of people will be diagnosed with epilepsy during their lifetime, but about 70% of people with epilepsy eventually go into remission.

Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of additional treatments in people with drug-resistant epilepsy characterised by generalised seizures? We searched: Medline, Embase, The Cochrane Library, and other important databases up to April 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results: We found four studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions: In this systematic review we present information relating to the effectiveness and safety on the addition of the following interventions: lacosamide, lamotrigine, levetiracetam, perampanel, and zonisamide versus the addition of placebo.

本刊更多论文

癫痫（全身性癫痫发作）。

简介约有 3% 的人在一生中会被诊断出患有癫痫，但约有 70% 的癫痫患者最终会得到缓解：我们进行了一项系统回顾，旨在回答以下临床问题：对于以全身性癫痫发作为特征的耐药性癫痫患者，额外治疗的效果如何？我们检索了Medline、Embase、Cochrane 图书馆和其他重要数据库（截至 2014 年 4 月）（临床证据综述会定期更新；请在我们的网站上查看本综述的最新版本）。我们还纳入了美国食品药品管理局 (FDA) 和英国药品与保健品监管局 (MHRA) 等相关机构发布的危害警报：我们发现有四项研究符合纳入标准。我们对干预措施的证据质量进行了 GRADE 评估：在本系统综述中，我们介绍了添加以下干预措施的有效性和安全性：拉科萨胺、拉莫三嗪、左乙拉西坦、培南帕奈和唑尼沙胺与添加安慰剂的对比。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMJ clinical evidence

自引率

0.00%

发文量